Group 1 - The core viewpoint of the report indicates that autologous CAR-T therapies face challenges due to complex preparation processes and high costs, especially with the emergence of TCE therapies showing comparable efficacy [1] - The global sales of autologous CAR-T therapies are projected to reach approximately $5.9 billion by 2025, reflecting a year-on-year growth of 30% [1] - The ASH 2025 conference revealed data from the MajesTEC-3 study, demonstrating that BCMATCE combined with daratumumab shows efficacy comparable to CARVYKTI, with better progression-free survival (PFS) rates, highlighting the need for breakthroughs in autologous CAR-T therapies [1] Group 2 - In vivo CAR-T therapies, which are simpler to produce and less costly, are seen as having significant potential, with over 20 clinical-stage in vivo CAR-T pipelines currently in early development [2] - Five in vivo CAR-T products have reported human data, showing short-term efficacy comparable to autologous CAR-T, with some products exhibiting superior safety profiles [2] - LNP vector products require multiple doses but have shown excellent safety, with preliminary efficacy signals observed in autoimmune diseases, indicating potential future success in this area [2] Group 3 - Since 2025, over 10 transactions related to in vivo CAR-T have occurred, with major pharmaceutical companies like AstraZeneca, AbbVie, and BMS actively investing in this space [3] - The report anticipates the release of over ten new clinical data readouts this year, many of which will be first-time results from pipelines that previously disclosed early data [3] - The clinical performance of in vivo CAR-T has been preliminarily validated, with increasing certainty in the technology's pathway, suggesting it may become the mainstream form of CAR-T therapy in the future [3]

Financial Data and Key Metrics Changes - Research and development (R&D) expenses decreased to $13.7 million for Q2 2025 from $16.2 million in Q2 2024, a reduction of $2.5 million primarily due to workforce reduction and program prioritization [11][12] - General and administrative (G&A) expenses were $5 million for Q2 2025, down from $5.8 million in Q2 2024, reflecting lower stock-based compensation and headcount-related expenses [12] - Net loss for Q2 2025 was $18.7 million compared to a net loss of $21.1 million in Q2 2024, indicating improved financial performance [12] - Cash and cash equivalents as of June 30, 2025, were $18.2 million, down from $49 million as of December 31, 2024, highlighting a significant cash burn [13] Business Line Data and Key Metrics Changes - The dual conditionally binding EpCAM CD3 T cell engager BA-3182 is showing promising results in its Phase 1 dose escalation study, with evidence of objective tumor reductions in patients with various solid tumors [5][6] - The CABWAR2 ADC OSV demonstrated an overall response rate (ORR) of 45% in patients with metastatic HPV-positive head and neck cancer, significantly outperforming the standard of care [8] - The McVe ADC has shown exceptional overall survival rates among heavily pretreated patients with MKRAS non-small cell lung cancer, with one-year and two-year landmark survival rates of 67% and 59%, respectively [9] Market Data and Key Metrics Changes - The company is focusing on indications with high unmet needs, such as colorectal cancer and cholangiocarcinoma, which have shown high expression of EpCAM and limited available therapies [18][19] - The company is progressing with partnering discussions across its CAB portfolio, indicating a strategic focus on collaboration for development and commercialization [10] Company Strategy and Development Direction - The company plans to present its strategy to NASDAQ to regain compliance with listing requirements, indicating a proactive approach to maintain its market position [10] - The company is positioning its OSV asset for a planned Phase III study and is seeking FDA guidance, reflecting a commitment to advancing its clinical pipeline [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in closing one or more partnering transactions this year, which could enhance financial stability and support key clinical activities [14][25] - The company is managing cash resources carefully and expects quarterly cash burn to decrease as it completes Phase II clinical trials [13][14] Other Important Information - The company has completed due diligence for one of its assets and is at the term sheet stage for a potential partnership, indicating progress in its strategic initiatives [10][11] Q&A Session Summary Question: Regarding the expansion cohort study, which indication is being pursued? - Management indicated that colorectal cancer is particularly attractive due to high EpCAM expression and unmet needs, although no formal decision has been made yet [18] Question: What are the tumor reduction levels for patients in the colorectal cancer cohort? - Management confirmed three patients with colorectal cancer have shown tumor reductions of -6%, -8%, and -10%, with additional patients in other cohorts also showing reductions [20] Question: Will there be updates on dosing cohorts? - Management stated that updates will be provided later this year, potentially during the ESMO meeting in October [22]